SY-1425 Combination Shows Promise in Acute Myeloid Leukemia Subgroup

Treatment with SY-1425 in combination with azacitidine induced a 62% complete response rate with incomplete blood count recovery rate among unfit patients with RARA-positive AML.

Source: CancerNetwork - October 31, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news